Hong Kong Healthtech Stock News

Recent share performance and business snapshot XtalPi Holdings (SEHK:2228) has drawn attention after a mixed period for the stock, with the share price down 4.2% on the day and lower over the past month and past 3 months. For context, the company reports HK$802.623 million in revenue and HK$123.747 million in net income, with annual revenue growth of 26.38% and net income growth of 62.44%, and a market cap of about HK$35.46b. See our latest analysis for XtalPi Holdings. At a HK$8.24 share...

REPT BATTERO Energy (SEHK:666) drew attention at the 18th China International Battery Fair in Shenzhen, showcasing new high-capacity energy storage cells, ultra-fast charging vehicle batteries, and long-life commercial solutions focused on safety, efficiency, and performance. See our latest analysis for REPT BATTERO Energy. These new product launches come as REPT BATTERO Energy trades at HK$15.21, with a 1-day share price return of 2.98% and a year to date share price return of 15.75%. The...

China Tobacco International (HK) (SEHK:6055) has drawn fresh investor attention after shareholders approved a final dividend of HK$0.33 per share for 2025 at the annual general meeting held on 26 May 2026. See our latest analysis for China Tobacco International (HK). The final dividend decision comes after a sharp 17.5% decline in the 30 day share price return and a 43.1% fall over 90 days, even though the 3 year total shareholder return is up 178.65%. This suggests long term holders have...

China Next-Gen Commerce and Supply Chain (SEHK:3928) has just posted its H1 2026 scorecard, with trailing 12 month revenue of about S$46.0 million and a loss of S$6.9 million, which translates to a trailing EPS of S$0.013931 loss. Looking back over recent halves, the company has seen revenue move from S$32.35 million in H2 2024 to S$31.96 million in H1 2025 and S$29.70 million in H2 2025, while net income shifted from a loss of S$1.04 million in H2 2024 to a profit of S$0.41 million in H1...

Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing recently reported positive Phase III data for bepirovirsen in chronic hepatitis B and secured China NMPA approval for naldemedine to treat opioid-induced constipation in adults. The bepirovirsen data point to materially higher functional cure rates than current lifelong therapies, highlighting Sino Biopharmaceutical’s role in advancing virus control and cancer risk reduction. We’ll now examine how bepirovirsen’s functional cure potential...

Today we're going to take a look at the well-established Kingboard Laminates Holdings Limited ( HKG:1888 ). The...

First Tractor Company Limited ( HKG:38 ) is about to trade ex-dividend in the next 3 days. The ex-dividend date is...

CSPC Pharmaceutical Group Limited ( HKG:1093 ) shareholders (or potential shareholders) will be happy to see that the...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Chu Kong...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Goldlion Holdings Limited ( HKG:533 ) stock is about to trade ex-dividend in three days. The ex-dividend date is...

Readers hoping to buy Wong's International Holdings Limited ( HKG:99 ) for its dividend will need to make their move...

Readers hoping to buy Henderson Land Development Company Limited ( HKG:12 ) for its dividend will need to make their...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Consun Pharmaceutical Group (SEHK:1681) has approved a final dividend of HK$0.40 per share at its 26 May 2026 AGM, linked to its financial results for the year ended 31 December 2025. See our latest analysis for Consun Pharmaceutical Group. The stock has eased back recently, with the 30 day share price return down 11.32% and the 90 day share price return down 21.22%. However, the 1 year total shareholder return of 40.06% and 3 year total shareholder return of almost 3x suggest longer term...

China Resources Building Materials Technology Holdings (SEHK:1313) has approved a final ordinary dividend of HK$0.024 per share for the 2025 financial year, with payment scheduled for 22 July 2026. See our latest analysis for China Resources Building Materials Technology Holdings. The HK$1.25 share price has been under pressure, with the 30 day share price return down 10.07% and the year to date share price return down 21.88%. The 1 year total shareholder return has declined 23.20%,...

Bank of China (SEHK:3988) has drawn investor attention after recent share price moves, with the stock showing different return patterns over the past week, month and past 3 months. At Friday’s close, it traded at HK$5.21. See our latest analysis for Bank of China. Stepping back from the latest move, Bank of China’s recent 1-day share price return of 1.56% sits within a broader pattern where its year-to-date share price return of 15.01% and 1-year total shareholder return of 17.28% point to...

Last week saw the newest annual earnings release from Topsports International Holdings Limited ( HKG:6110 ), an...

The quarterly results for Kuaishou Technology ( HKG:1024 ) were released last week, making it a good time to revisit...

Shanghai Haohai Biological Technology Co., Ltd. ( HKG:6826 ) is about to trade ex-dividend in the next 4 days. The...

Shareholders might have noticed that CSPC Pharmaceutical Group Limited ( HKG:1093 ) filed its quarterly result this...

Readers hoping to buy The Hong Kong and China Gas Company Limited ( HKG:3 ) for its dividend will need to make their...

If you are wondering whether Xiaomi's current share price reflects its true worth, the recent moves in the stock give plenty to think about. The stock is down 6.5% over the past week, 7.0% over the past month, 30.4% year to date and 45.0% over the past year, while the 3 year return stands at 161.1%. This mix of shorter term weakness and stronger 3 year performance has kept Xiaomi on many investors' watchlists, as it raises questions about how the market is reassessing growth expectations and...

Those following along with Mao Geping Cosmetics Co., Ltd. ( HKG:1318 ) will no doubt be intrigued by the recent...